Enanta Pharmaceuticals, Inc. (ENTA)
11.47
+0.29
(+2.59%)
USD |
NASDAQ |
Oct 15, 16:00
11.45
-0.02
(-0.17%)
After-Hours: 20:00
Enanta Pharmaceuticals Research and Development Expense (Quarterly) : 22.13M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 22.13M |
| March 31, 2026 | 19.44M |
| December 31, 2025 | 20.86M |
| September 30, 2025 | 23.81M |
| June 30, 2025 | 27.21M |
| March 31, 2025 | 28.06M |
| December 31, 2024 | 27.66M |
| September 30, 2024 | 30.78M |
| June 30, 2024 | 28.74M |
| March 31, 2024 | 35.58M |
| December 31, 2023 | 36.37M |
| September 30, 2023 | 36.17M |
| June 30, 2023 | 42.99M |
| March 31, 2023 | 43.47M |
| December 31, 2022 | 40.90M |
| September 30, 2022 | 34.80M |
| June 30, 2022 | 39.09M |
| March 31, 2022 | 42.09M |
| December 31, 2021 | 48.55M |
| September 30, 2021 | 48.95M |
| June 30, 2021 | 46.99M |
| March 31, 2021 | 41.51M |
| December 31, 2020 | 36.66M |
| September 30, 2020 | 36.69M |
| June 30, 2020 | 34.68M |
| Date | Value |
|---|---|
| March 31, 2020 | 32.61M |
| December 31, 2019 | 32.78M |
| September 30, 2019 | 38.72M |
| June 30, 2019 | 34.46M |
| March 31, 2019 | 34.16M |
| December 31, 2018 | 34.88M |
| September 30, 2018 | 26.92M |
| June 30, 2018 | 28.49M |
| March 31, 2018 | 21.48M |
| December 31, 2017 | 17.96M |
| September 30, 2017 | 16.51M |
| June 30, 2017 | 15.41M |
| March 31, 2017 | 13.00M |
| December 31, 2016 | 12.53M |
| September 30, 2016 | 11.50M |
| June 30, 2016 | 10.78M |
| March 31, 2016 | 9.143M |
| December 31, 2015 | 9.033M |
| September 30, 2015 | 7.049M |
| June 30, 2015 | 6.253M |
| March 31, 2015 | 5.368M |
| December 31, 2014 | 4.519M |
| September 30, 2014 | 5.202M |
| June 30, 2014 | 4.553M |
| March 31, 2014 | 4.722M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 20.40M |
| Coherus Oncology, Inc. | 20.58M |
| BridgeBio Pharma, Inc. | 149.45M |
| RenovoRx, Inc. | 1.20M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |